Two million Brits warned to watch for life-threatening symptoms after antidepressant mix-up.

Millions of Britons taking a popular antidepressant have received an urgent directive to monitor for signs of a dangerous medical condition following the discovery that specific batches of the medication were contaminated with a different drug. More than two million people are affected by this mix-up, which involves sertraline packets mistakenly containing tablets of citalopram. The Medicines and Healthcare products Regulatory Agency (MHRA) has instructed patients to seek immediate medical help if they experience a rapid heartbeat, nausea, headaches, or sleep disturbances.

These symptoms may indicate serotonin syndrome, a potentially life-threatening reaction caused by the accidental mixing or alternating of two antidepressants. According to NHS guidance, the condition can also manifest as confusion, agitation, sweating, and shaking. In severe instances, the reaction can progress to coma, a prolonged state of deep unconsciousness. The recall specifically targets 100mg film-coated sertraline tablets with batch number V2500425 and an expiry date of May 2028. Anyone who identifies rogue strips of citalopram in their medication is advised to contact their pharmacy immediately.

Both sertraline and citalopram belong to the class of selective serotonin reuptake inhibitors (SSRIs), which are widely prescribed to treat depression, anxiety, and other mood disorders by regulating serotonin levels in the brain. However, experts warn that combining or alternating SSRIs can be dangerous and even fatal. Dr Alison Cave, chief safety officer for the MHRA, addressed the recall on Tuesday, stating, "Patients who have accidentally taken citalopram instead of – or as well as – sertraline, may experience some heightened serotonergic side effects."

Official NHS guidance emphasizes that symptoms of serotonin syndrome range from mild to severe and require urgent treatment. Physical manifestations include hypertension, or high blood pressure; tachycardia, where the heart rate exceeds 100 beats per minute; and hyperthermia, which can raise body temperature to approximately 40C. Additional warning signs include dry eyes, unusually active bowel sounds, excessive sweating, tremors, and clonus, defined as involuntary, rhythmic muscle contractions. Patients may also suffer from muscle and joint stiffness, along with hyperreflexia, a condition where reflexes become unusually exaggerated.

Mental symptoms associated with this condition include feelings of anxiety, agitation, and confusion. For confidential support regarding these health concerns, individuals are encouraged to call the Samaritans on 116 123, visit samaritans.org, or access resources at https://www.thecalmzone.net/get-support. The regulatory response underscores the critical importance of verifying medication contents to ensure patient safety and prevent adverse health outcomes.

The most severe outcomes of improper medication management can culminate in a prolonged state of deep unconsciousness known as a coma. These fears intensified recently following the tragic suicide of Thomas Kingston, the former husband of Lady Gabriella Windsor, in February 2024. The 45-year-old, who married the royal at Windsor Castle in 2019 in a ceremony attended by the late Queen, took his own life after being prescribed sertraline and citalopram for anxiety by a physician at Buckingham Palace.

Senior coroner Katy Skerrett highlighted critical gaps in safety protocols in a prevention of future deaths report released last year. She questioned whether there is sufficient communication regarding suicide risks associated with these specific pills and challenged the appropriateness of current guidance that encourages patients to persist with medication even when adverse side effects emerge. This case is not isolated; more than 40 other prevention of future deaths reports have cited the use of either citalopram or sertraline by the deceased individuals involved. These documents expose a spectrum of systemic failures, including a lack of patient alerts on potential side effects, breaches of prescribing standards, insufficient patient reviews, and a failure to record behavioral changes while patients are on the drugs.

A specific recall incident underscores the physical dangers of these errors. The manufacturing company behind the affected batch of sertraline has received a complaint from an adult patient who suffered a headache, only to discover their prescription strip actually contained citalopram tablets. Investigators determined that both drugs were manufactured at the same facility, and the mix-up occurred during the secondary packing process where strips were incorrectly inserted into cardboard packaging.

In response, pharmacists and healthcare professionals dispensing these antidepressants have been directed to contact any patients who may have received the wrong medication and arrange for its immediate return. The affected batch entered distribution on November 28, 2025, prompting a directive for GPs and clinicians to review ongoing prescriptions and determine if new supplies are necessary. The Medicines and Healthcare products Regulatory Agency (MHRA) issued a stark warning to specific demographics, advising that patients over 65, those under 18, and individuals with heart or liver conditions must exercise extreme caution. Furthermore, the watchdog instructed healthcare providers to cease supplying the contaminated batch and return all remaining stock to suppliers. Any suspected adverse reactions must be reported through the Yellow Card scheme. For those seeking confidential support, the Samaritans remain available at 116 123, via samaritans.org, or through https://www.thecalmzone.net/get-support.